Target- |
Mechanism- |
|
|
|
Inactive Indication- |
Drug Highest PhasePreclinical |
First Approval Ctry. / Loc.- |
First Approval Date- |
|
|
|
|
|
Inactive Indication- |
Drug Highest PhasePreclinical |
First Approval Ctry. / Loc.- |
First Approval Date- |
|
MechanismPfbc1 inhibitors |
Active Org.- |
|
Active Indication- |
|
Drug Highest PhasePending |
First Approval Ctry. / Loc.- |
First Approval Date- |
A randomised, double-blind, placebo-controlled, parallel-group study to evaluate the efficacy and safety of 500µg of GW799943X administered once-daily in the morning, 500µg of GW799943X administered once-daily in the evening, and 1000µg GW799943X administered once-daily in the morning compared with placebo and fluticasone propionate 250µg twice daily, all delivered by ROTADISK/DISKHALER for 28 days in subjects with persistent bronchial asthma symptomatic on low-dose ICS.
A randomized, double blind (sponsor open), comparative, multicenter study to evaluate the safety and efficacy of subcutaneous belimumab (GSK1550188) and intravenous rituximab coadministration in subjects with primary Sjögren’s syndrome.
A randomized, multicentre, open-label Phase III study of lapatinib in combination with trastuzumab versus lapatinib monotherapy in subjects with metastatic breast cancer whose disease has progressed on trastuzumab-containing regimens
100 Clinical Results associated with GlaxoSmithKline (China) R&D Co., Ltd.
0 Patents (Medical) associated with GlaxoSmithKline (China) R&D Co., Ltd.
100 Deals associated with GlaxoSmithKline (China) R&D Co., Ltd.
100 Translational Medicine associated with GlaxoSmithKline (China) R&D Co., Ltd.